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Targeted therapies exploiting specific molecular defects in cancer cells promise to overcome roadblocks in
the development of effective anticancer drugs. A recent report in theNew England Journal of Medicine on the
early clinical evaluation of Olaparib in cancers lacking theBRCA1 orBRCA2 genes exemplifies this promising
new trend.Developing drugs that are clinically effec-
tive against cancer remains almost as
risky, protracted, and expensive today as
it was a decade ago, defying earlier
optimism that rapid advances in our
understanding of cancer biology might
dramatically alter this trend. One major
barrier has been the difficulty in defining
the clinical settings in which new agents
will be effective. This has led to high rates
of attrition when drug candidates that
successfully pass Phase I trials (assessing
safety and tolerability) are progressed
through later-phase trials that test their
clinical efficacy. Approaches targeting
molecular defects that drive specific
forms of cancer offer an exciting spring-
board to jump the ‘‘efficacy barrier.’’ New
drugs that inhibit oncogenic pathways
essential for tumor outgrowth can achieve
dramatic therapeutic outcomes (e.g.,
Demetri et al., 2002; Slamon et al., 2001),
and careful matching of existing therapies
to the genetic make-up of a tumor can
considerably improve efficacy (e.g., Hegi
et al., 2005). Fong and colleagues now
further exemplify this exciting trend
through the results of a Phase I clinical trial
testing Olaparib, a potent inhibitor of the
DNA repair enzyme poly-ADP ribose poly-
merase 1 (PARP1), in cancers lacking the
BRCA1 or BRCA2 genes (Fong et al.,
2009).
Genetic analyses of families exhibiting
a high incidence of breast and ovarian
cancer led to the identification of BRCA1
and BRCA2 in 1994 and 1995 (reviewed
in Szabo and King, 1995). These studies
found that the inheritance of heterozy-
gous germline mutations in either one of
these genes predispose carriers to cancer
with a risk approaching 50%–70% by the
age of 60 years. The second allele isconsistently lost in the cancers arising in
these individuals; however, other tissues
remain heterozygous for the inherited
mutations.
Over a decade’s studies from many
laboratories have illuminated the biolog-
ical function of the BRCA gene products
and their role in cancer predisposition
(reviewed in Venkitaraman, 2009), thus
blazing the trail for clinical exploitation.
BRCA proteins bind and colocalize with
the eukaryal recombination enzyme
RAD51, regulating its cellular localization
and activity—a first clue to their indis-
pensable function in homologous DNA
recombination. This pathway normally
works to restart DNA replication forks
stalled at template lesions; therefore, its
inactivation in BRCA-deficient cells leads
to the collapse of stalled forks (e.g.,
Lomonosov et al., 2003), triggering DNA
breakage and cell death when exposed
to replication-blocking or DNA cross-link-
ing agents. PARP1 inhibitors spectacu-
larly exploit this defect unveiled by BRCA
inactivation (Bryant et al., 2005; Farmer
et al., 2005); in this setting, it is proposed
they create single-strand DNA gaps at the
sites of base lesions, stalling replication
forks and leading to cytotoxic double-
stranded DNA breaks. In vitro, these com-
pounds are 2 to 3 orders of magnitude
more lethal for homozygously BRCA-defi-
cient cells than their wild-type or hetero-
zygous counterparts.
Fong and colleagues have now under-
taken aPhase I trial ofOlaparib. In addition
to assessing the drug’s safety, tolerability,
and pharmacology, they used a design
that helped to give early indications of
its efficacy. Thus, after the traditional
dose-escalation stage to establish the
maximum tolerated dose, Fong et al.Cancer Ceexpanded their trial to enrich for patients
who carried germline mutations in
BRCA1 or BRCA2 to test the hypothesis
that the drug would elicit an antitumor
response in this cohort. All of the 60
participants had received previous treat-
ments; about half had tumors associated
with cancer predisposition inBRCAmuta-
tion carriers. Sixteen of the 21 ovarian
cancer patients, 3 of the 9 breast cancer
patients, and 1 of the 3 prostate cancer
patients carried BRCA mutations. Three
additional patients either had a family
history strongly indicative of BRCA-muta-
tion-carrier statusorwere knownmutation
carriers who had cancers at atypical
sites. Thus, overall, the trial compared 23
patients with BRCA mutations, suffering
predominantly from cancers of the ovary,
breast, or prostate, with 37 noncarrier
patients whose malignancies largely orig-
inated in other tissues (e.g., colorectal
cancer and melanoma).
Olaparibwaswell toleratedwhenadmin-
istered as a single agent, compared to
conventional chemotherapeutic regimes.
Safety considerations, as well as pharma-
cokinetic and pharmacodynamic evalua-
tion, led to the continuous administration
of 200 mg, twice daily, being adopted for
the majority of patients in the expansion
stage of the trial, when the clinical efficacy
of Olaparib was assessed.
The preliminary evaluation of antitumor
responses achieved using Olaparib
showed very encouraging results. Of the
23 BRCA mutation carriers, 2 could not
be evaluated for clinical reasons and 2
who had tumors not typically associated
withBRCA-deficiencyprogresseddespite
receiving Olaparib. Ten of the 19 remain-
ing patients (53%) showed an objective
antitumor response according to RECISTll 16, August 4, 2009 ª2009 Elsevier Inc. 89
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Previewscriteria and/or >50% reduction in the
serum markers CA-125 or PSA in patients
with ovarian or prostate cancer, respec-
tively, sustained for >4 weeks. Two further
mutation carriers had evidence of
stable disease. In contrast, no objective
responses were observed in patients
whowere noncarriers ofBRCAmutations.
These preliminary results strongly
suggest that PARP1 inhibitors, even used
as single agents, will be clinically effective
in treating breast, ovarian or prostate
carcinoma associated with germline
BRCA mutations. Further clinical investi-
gation will be needed to confirm this and
to optimize dosing for particular clinical
indications. It is encouraging in this latter
context that BRCA mutation carriers ex-
hibited no higher frequency or severity of
adverse events than noncarriers, suggest-
ing that Olaparib selectively affects cells
that have lost bothBRCA alleles, over het-
erozygously mutant but otherwise normal
cells. Also, there appears to be a generous
window between the minimum dose
required to demonstrate a sustainedphar-
macodynamic effect (at doses >60 mg
twice daily, there was sustained inhibition
of PARP1 activity in peripheral blood
mononuclear cells by 90%) and the
maximum tolerated dose (400 mg
twice daily), leaving headroom for further
optimization.
Nonetheless,whywere >35%of tumors
in BRCA mutation carriers unresponsive
to Olaparib? Several explanations are
notionally possible. In vitro evidence
suggests that the degree of sensitivity to
PARP inhibition may depend on the
degree towhich homologousDNA recom-
bination is compromised in BRCAmutant
cells; this may vary according to not only
the specific BRCA gene mutation and
residual function, but also other genetic
alterations in the cancer cells. Reversion
of BRCA gene functions associated with
the emergence of resistance to therapy
has been observed in experimental
systems; sinceall of thepatients in this trial
had received prior treatments, presum-
ably including replication-blocking or
DNA cross-linking agents, it is possible
that reversion had been selected out in90 Cancer Cell 16, August 4, 2009 ª2009 Elsome cases. Last but not least, tumor
exposure to Olaparib could conceivably
differ between different cases due to
patient or cancer characteristics.
The absence of serious adverse events
is very promising. One caveat, however,
is that this trial has so far assessed rela-
tively short exposures to Olaparib in the
majority of patients. Whether longer-term
or chronic toxicities will emerge due to the
systemic suppression of PARP1-depen-
dent DNA repair, which acts to resolve
lesions generated endogenously in many
normal cells, needs to be assessed. One
result concerning pharmacodynamics in
the report is salient in this regard. The
investigators examined cells in hair folli-
cles plucked from the eyebrow of patients
exposed to Olaparib for the presence of
nuclear gH2AX foci, a reliable marker of
double-stranded DNA breaks. These cells
in BRCA-mutation carriers are expected
to be heterozygous for the mutation,
whereas in noncarriers, they have wild-
type BRCA genes. However, Olaparib
exposure rapidly induced DNA breakage
in these cells, with the kinetics andmagni-
tude of this response paralleling the phar-
macokinetics of the drug. This suggests
that PARP1 inhibition causes genotoxic
lesions in normal as well as BRCA-defi-
cient cancer cells but triggers cell death
only in the latter, perhaps due to their
failure to repair the lesions.
This intriguing result raises questions
requiring further consideration. First, will
the therapeutic window for Olaparib be
as favorable with chronic as opposed to
short-term treatment, or with increased
drug exposure? This question comes from
the possibility that there may be a low but
significant frequency of misrepair, or even
lack of repair, of Olaparib-induced lesions
in nontumor cells. Second, will the selec-
tivity of Olaparib be compromised if it
were to be combined with other DNA-
damagingor DNA-repair-inhibiting drugs?
Such combinations could conceivably
potentiate Olaparib-induced DNA breaks
or modify their repair.
An interesting possibility discussed by
Fong et al. is that Olaparib might prove
to be useful in the treatment of cancerssevier Inc.that occur in individuals without germline
BRCA mutations but exhibit defects in
homologous recombination. This is of
potential importance because BRCA
mutations are found in only a small
minority of breast and ovarian cancers.
This clinical trial provides no evidence so
far to support this notion. Despite the
caveat that the trial involved only a small
number of patients, the results suggest
defective homologous DNA recombina-
tion may be uncommon in ovarian and
other tumors in nonmutation carriers used
as controls.
Like all good studies, the work of Fong
et al. raises as many questions as it
answers. Nonetheless, it represents an
important step in the evolution of ratio-
nale-driven, targeted cancer therapies
from the laboratory to the clinic.
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